1 Department of Molecular Biology,
2 Department of Pathology, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd., Dallas, TX 75390-9148, USA
* These authors contributed equally to this work
Author for correspondence (e-mail: eolson{at}hamon.swmed.edu)
Accepted August 20, 2001
![]() |
SUMMARY |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key words: Skeletal muscle, MEF2C, Mouse, bHLH, MEF2, Myogenesis
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Members of the MyoD family share homology in a basic helix-loop-helix (bHLH) region that mediates dimerization and binding to the E-box consensus sequence (CANNTG), which is found in the control regions of many muscle-specific genes (Olson and Klein, 1994). The bHLH region also associates with MEF2 transcription factors, which lack myogenic activity alone, but potentiate the muscle-inducing activity of myogenic bHLH proteins and are required for the activation of muscle differentiation genes (Molkentin et al., 1995). The four vertebrate MEF2 factors MEF2A, MEF2B, MEF2C and MEF2D belong to the MADS (MCM1, agamous, deficiens, SRF) family of transcription factors (Black and Olson, 1998). The MADS domain mediates dimerization, association with myogenic bHLH proteins, and binding to an A/T-rich DNA sequence associated with muscle-specific genes (Gossett et al., 1989; Pollock and Treisman, 1991).
In contrast to the skeletal muscle specificity of myogenic bHLH factors, MEF2 factors are expressed in skeletal, cardiac and smooth muscle cells, as well as in neurons (Breitbart et al., 1993; Chambers et al., 1992; Yu et al., 1992; Leifer et al., 1993; Martin et al., 1993, Martin et al., 1994; Lyons et al., 1995; Edmondson et al., 1994; Ticho et al., 1996), and at lower levels in several other cell types. During embryogenesis, Mef2c is expressed at the onset of differentiation of the cardiac and skeletal muscle lineages and is followed by expression of the other MEF2 genes (Edmondson et al., 1994). Mice that lack Mef2c die at about E9.5 from cardiovascular defects, precluding analysis of the role of Mef2c in skeletal muscle development in vivo (Lin et al., 1997). Mice homozygous for mutations in Mef2a or Mef2b are viable, whereas mice lacking Mef2d die prior to gastrulation (our unpublished results). Loss-of-function mutations of the single Mef2 gene in Drosophila result in a block to differentiation of all muscle cell types (Lilly et al., 1995; Bour et al., 1995; Ranganayakulu et al., 1995), indicating that MEF2 genes are required for muscle differentiation.
In addition to activating subordinate muscle structural genes, myogenic bHLH and MEF2 factors auto- and crossregulate the expression of one another. Forced expression of myogenic bHLH genes in non-muscle cell types is sufficient to activate expression of the endogenous myogenic bHLH genes and to upregulate expression of MEF2 genes (Lassar et al., 1991; Cserjesi and Olson, 1991). MEF2 alone cannot induce expression of myogenic bHLH genes (Molkentin et al., 1995), but the promoters of the myogenin and Mrf4 genes contain binding sites for myogenic bHLH and MEF2 factors that control transcription during myoblast differentiation in vivo and in vitro (Cheng et al., 1993; Yee and Rigby, 1993; Black et al., 1995; Naidu et al., 1995). Binding of MEF2 to these sites provides a mechanism for amplifying the expression of these regulatory genes and stabilizing the muscle phenotype. Whether myogenic bHLH proteins act directly on MEF2 genes to upregulate their expression, or whether they induce MEF2 expression through an indirect mechanism is unknown because regulatory elements for vertebrate MEF2 genes have not been identified.
To further understand the mechanisms that regulate MEF2 expression during myogenesis, we sought to identify cis-regulatory elements responsible for transcription of the mouse Mef2c gene during skeletal muscle development. We describe a novel skeletal muscle-specific control region upstream of the Mef2c gene that is sufficient to direct the expression of a lacZ transgene in a spatiotemporal expression pattern that mimics that of the endogenous gene during mouse development. Mutational analysis of this control region shows that it is a direct target for myogenic bHLH and MEF2 factors in vivo, revealing a transcriptional circuit through which these transcription factors induce, amplify and maintain Mef2c expression during muscle development.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
An aliquot of the first PCR products was also used for subsequent nested PCR. Amplified cDNAs were gel-purified and subcloned into the pGEM-T-Easy vector (Promega) and sequenced. Multiple overlapping clones were isolated through this approach.
Genomic library screening, DNA cloning, mapping and sequencing
A mouse genomic library (Stratagene) was screened using a cDNA fragment obtained from 5'-RACE as a probe. Three positive clones were isolated and sub-cloned into the pBlueScript vector (Stratagene). Restriction mapping and DNA sequencing were performed as described previously (Lin et al., 1998).
Generation and analysis of transgenic mice
Different fragments of the Mef2c 5-flanking region were subcloned into the hsp68-lacZ vector (Kothary et al., 1989) to make reporter constructs (detailed in Fig. 2). Transgenes were prepared and injected into the male pronuclei of fertilized oocytes from B6C3F1 mice as described previously (Cheng et al., 1992). Injected oocytes were then transplanted into ICR pseudopregnant females and embryos were harvested at the desired embryonic or neonatal time points indicated in the text and figure legends.
|
Mice carrying lacZ transgenes were identified by PCR analysis. Genomic DNA isolated from tail biopsies or embryonic yolk sacs was digested in lysis buffer (10 mM Tris (pH 8.0), 25 mM EDTA, 100 mM NaCl, 1% SDS, 0.2 mg/ml Proteinase K) at 55°C overnight, followed by removal of protein by phenol/chloroform extraction and ethanol precipitation. A typical PCR reaction contained genomic DNA template, 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 1.5 mM MgCl2, 0.1% Triton X-100, 0.16 mM of each dNTP, 1 µM of each primer and 2.5U Taq polymerase (Promega) in a 25 µl total volume. A typical temperature profile included 32 cycles of DNA strand melting at 95°C for 30 seconds, primer annealing at 55°C for 30 seconds and polymerization at 72°C for 30 seconds. lacZ genotype analysis was performed by PCR on genomic DNA using the following primers: 5'-CAAACTGGCAGATGCACGGTTAC-3' and 5'-CAGTACAGCGCGGCTGAAATC-3', producing a 450 bp lacZ-specific product.
The preparation, sectioning and staining of embryos was performed using standard procedures. Briefly, ß-galactosidase-stained embryos were post-fixed in 4% paraformaldehyde in PBS overnight at 4°C and embedded in paraffin after a stepwise dehydration with progressively higher concentrations of ethanol and two changes of xylene. Embryos were sectioned in increments of 5-7 µm. Sections were counterstained with nuclear Fast Red and cover-slipped with cytoseal or permount.
Gel mobility shift assays
Proteins for electrophoretic mobility shift assays (EMSA) were produced using the TNT T3/T7 Coupled Reticulocyte Lysate System (Promega). The DNA templates used for in vitro transcription of mouse MyoD, E12 and Myc-tagged MEF2C were: EMSV-MyoD, pCITE-E12 and pcDNA3.1-MEF2C-Myc, respectively. pEMSV-MyoD consists of a full length MyoD cDNA subcloned into the expression vector pEMSVscribe (Harland and Weintraub, 1985). pCITE-E12 contains the E12 cDNA inserted into the pCITE expression vector (Novagen). pcDNA3.1-MEF2C-Myc contains the full-length mouse MEF2C cDNA with a C-terminal Myc epitope tag (McKinsey et al., 2000a; McKinsey et al., 2000b) subcloned into the pcDNA3.1 expression vector (Invitrogen). To ensure that proteins were appropriately translated, parallel transcription-translation reactions were performed in the presence of [35S]methionine, separated by 10% SDS-PAGE and visualized using autoradiography.
The sequences of the sense strands of the oligonucleotides used as probes in the gel mobility shift assays were as follows: MEF2 site, 5'-ACCTTTACAGCTAAATTTACTCCAGAGTG-3'; and E-box, 5'-GAGTGACATGAACAGGTGCACCCTGGCCT-3'.
Gel mobility shift assays were also performed with oligonucleotides corresponding to the high-affinity right E-box (Chakraborty et al., 1991) and MEF2 sites (Cserjesi et al., 1994) from the MCK enhancer as a positive control. The oligonucleotides were generated with four extra nucleotides, GAGG, at their 5' ends. Oligonucleotides were annealed at a concentration of 100 ng/µl and were end-labeled with [-32P]dCTP using the Klenow fragment of DNA polymerase I. All binding reactions were performed using 2 µg poly(dI:dC) and 100,000 cpm of probe in a total volume of 20 µl of binding buffer (400 mM KCl, 150 mM Hepes (pH 7.9), 10 mM EDTA, 5 mM DTT, 50% glycerol). Where indicated, unlabelled annealed oligonucleotide was used as competitor. Reactions were incubated at room temperature for 15-20 minutes. Where indicated, mouse monoclonal anti-Myc (Santa Cruz) and anti-MyoD (Pharmingen) antibodies were added to the reactions at concentrations of 45 and 33 ng/µl, respectively, and incubated for an additional 10-15 minutes. Binding reactions were analyzed by electrophoresis on 4% (MyoD binding) and 5% (MEF2C binding) non-denaturing polyacrylamide gels in 0.5x TBE. Gels were dried and binding was visualized by autoradiography.
Site-directed mutagenesis
Mutagenesis of the MEF2 site and E-box was achieved using the overlap extension method, previously described (Horton and Pease, 1991). The DNA template used for mutagenesis and cloned into pBlueScript (Stratagene) included the nucleotide region from 512 bp to +41 bp. Mutant PCR products were then sub-cloned into the pGEM-T-Easy Vector (Promega). Mutated fragments were then excised using endogenous flanking restriction enzyme sites and cloned into the appropriate transgenic expression vector. All mutations were confirmed by DNA sequencing.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The structure of the mouse Mef2c gene was characterized by genomic DNA sequencing and restriction mapping, as well as comparison of human and mouse genomic DNA sequences from several databases. The deduced structure of the mouse Mef2c gene is shown in Fig. 1A. The protein-coding region of the gene comprises 11 exons (exons 4-14) distributed over approximately 200 kb of genomic DNA. As reported previously, several exons are contained in all Mef2c transcripts, while others are used alternatively (Martin et al., 1993; McDermott et al., 1993). Based on RT-PCR analysis of RNA from different tissue sources and on the presence of exon sequences in expressed sequence tags, exons 6 and 7 appear to be mutually exclusive, with exon 6 being used in transcripts from heart and brain, and exon 7 being specific to skeletal muscle. Exons 9 and 14b are also detected in heart and brain transcripts, but not in skeletal muscle transcripts; and exon 11 is specific to brain. The AUG codon is contained in a 193 bp exon (exon 4) that, in skeletal muscle transcripts, is spliced to an approximately 250 bp exon (exon 1), located approximately 80 kb upstream. The sequence of the 5'-UTR from skeletal muscle Mef2c transcripts are shown in Fig. 1B.
|
Identification of the Mef2c skeletal muscle regulatory region
To search for the regulatory region responsible for skeletal muscle expression of Mef2c, we fused a series of 5' genomic fragments to the hsp68 basal promoter upstream of a lacZ reporter gene and tested for expression in F0 transgenic mouse embryos (Fig. 2). We initially included the hsp68 basal promoter in the transgene constructs because this promoter is extremely sensitive and permissive to heterologous enhancers (Lien et al., 1999; McFadden et al., 2000) and it therefore enabled us to search for potential Mef2c regulatory elements without knowing the precise location of the promoter. As shown in Fig. 3, the 6.6 kb region immediately 5' of the skeletal muscle-specific exon 1 was sufficient to direct strong skeletal muscle-specific expression in vivo (construct 1). As a positive control for lacZ transgene expression, a well-defined neural crest enhancer (NCE) of the mouse dHAND (Hand2 Mouse Genome Informatics) gene, which has been shown to be active specifically in the branchial arches of developing embryos (Charité et al., 2001), was fused upstream of this 6.6 kb genomic sequence. The NCE gave rise to an expression pattern in the branchial arches and their derivatives (Fig. 3), as predicted. Because this enhancer is active in cell types in which Mef2c is not expressed, we were able to use it initially to rapidly survey numerous genomic fragments for the Mef2c skeletal muscle enhancer by identifying embryos that contained lacZ transgenes integrated into regions of chromatin permissive to gene expression. Once we had identified the region of genomic DNA with skeletal muscle regulatory activity, we no longer included the NCE in subsequent transgenes. Expression from construct 1 was localized to the somite myotomes at E9.5-11.5 (Fig. 3A-D). At E14.5, this construct was highly active in differentiated skeletal muscle fibers throughout the body (Fig. 3E). No expression in other cell types, including cardiac and smooth muscle, was detected at any developmental stage examined.
|
|
|
|
Because construct 9 was expressed throughout the entire myotome, and was as strong as construct 7, we attempted to further localize the cis-regulatory elements within this fragment. Bisection of construct 7 into two fragments (512/174, construct 10, and 158/+4, construct 11) demonstrated that all of its transcriptional activity was contained in the 3' fragment (Fig. 6G,H and data not shown).
Together, the above results demonstrate the existence of two independent Mef2c regulatory regions capable of directing transcription in the skeletal muscle lineage. The region from 158/+4, which acts as a promoter, appears to be primarily responsible for the skeletal muscle-specific expression of Mef2c. This region can also direct muscle-specific expression in the opposite orientation when combined with the hsp68 promoter, which suggests that it can also act as an enhancer.
Regulation of the Mef2c skeletal muscle enhancer by MyoD and MEF2
The sequence of the minimal skeletal muscle regulatory region is shown in Fig. 7A. Comparison of the sequence from the mouse and human genes showed extensive cross-species homology (data not shown). Within the minimal regulatory region, we identified an E-box and a potential MEF2 site (Fig. 7A,B). To determine whether myogenic bHLH or MEF2 proteins could bind these sequences, we performed gel mobility shift assays using oligonucleotide probes and in vitro translated proteins. As shown in Fig. 7C, Myc-tagged MEF2C bound avidly to the MEF2 site-containing oligonucleotide and binding was competed by the cognate sequence, but not by a nonspecific sequence (data not shown). The identity of the MEF2C-containing complex was confirmed by its supershift with anti-Myc antibody. Similarly, the E-box-containing sequence was bound by MyoD/E12 heterodimers, which were supershifted with anti-MyoD antibody (Fig. 7D). Homodimers of MyoD or E12 showed only weak binding to this site.
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Our results are consistent with the possibility that the Mef2c gene is a direct target for transcriptional activation by myogenic bHLH and MEF2 proteins in the developing skeletal muscle lineage in vivo. These results confirm and extend previous findings that MEF2 DNA binding activity is upregulated by myogenic bHLH proteins (Lassar et al., 1991; Cserjesi and Olson, 1991) and reveal a direct positive feedback loop between these two classes of transcription factors. This is the first demonstration of a direct role of myogenic bHLH factors in the activation of MEF2 gene transcription in any organism.
Mef2c expression and skeletal muscle development
Skeletal muscle development is initiated in the rostral somites of the mouse embryo at E8.0 (Hauschka, 1994). Signals from the notochord induce cells from the ventral region of the somite to undergo an epithelial-to-mesenchymal transformation and migrate away from the somite, forming the sclerotome (Christ et al., 1978), which gives rise to the axial skeleton. The remaining epithelial cells of the dorsal somite give rise to the dermomyotome, which serves as the source of myogenic precursors of the trunk and limb musculature, and the myotome, from which the muscles of the back are derived (Denetclaw et al., 1997; Ordahl et al., 2001). Myf5 is the first marker of the skeletal muscle lineage and is expressed in the dorsomedial lip of the dermomyotome at E8.0 in the mouse followed soon after by the expression of myogenin, MRF4 and MyoD at E8.5, E9.5 and E10.5, (Sassoon et al., 1989; Ott et al., 1991; Hinterberger et al., 1991), respectively.
Like the myogenic bHLH transcription factors, MEF2 factors are expressed early in myogenic precursors and in developing skeletal muscle. Mef2c is the first member of the MEF2 family to be expressed in skeletal muscle in vivo; its expression is initially detected at E9.0 in the rostral myotomes at the onset of myocyte differentiation (Edmondson et al., 1994) and expression is maintained throughout skeletal muscle development. In the current study, we were able to detect expression of the Mef2c-lacZ transgene in the myotome as early as E9.0, throughout skeletal muscle development, and into adult muscle, recapitulating that of the endogenous Mef2c gene. The lag between the expression of Myf5/myogenin and Mef2c in developing somites suggests that the myogenic bHLH factors, but not MEF2C, are required for the initiation of skeletal muscle differentiation, whereas MEF2 proteins may be involved in the maintenance and/or amplification of the skeletal muscle differentiation program.
Regulation of Mef2c gene expression in skeletal muscle initiation versus amplification/maintenance
Forced expression of myogenic bHLH proteins in non-muscle cells is sufficient to upregulate MEF2 expression (Lassar et al., 1991; Cserjesi and Olson, 1991). Our results suggest that this reflects the direct binding of myogenic bHLH proteins to an E-box in the proximal promoter of the Mef2c gene. Our data also indicate that in the context of the Mef2c gene (512 to +41) region, this E-box is essential for the initial activation of Mef2c transcription in the skeletal muscle lineage. An E-box mutation in the Mef2c promoter completely abolished lacZ reporter expression at E9.5. Given that the E-box mutation also abolished expression at later stages of development, binding of myogenic bHLH proteins to this site also appears to be required for the maintenance of Mef2c expression. As Myf5 and myogenin are expressed prior to Mef2c, these factors are potential initiators of Mef2c transcription. In mature skeletal muscle fibers, it is likely that MRF4 maintains Mef2c expression, as this factor is the most highly expressed in postnatal muscle.
In contrast to the requirement of the E-box for initiation of Mef2c transcription, a mutation of the MEF2 site did not affect the timing for initial activation of the reporter gene such that weak lacZ expression was detected in the somites at E9.5. However, at later stages, this MEF2 site mutant was unable to maintain lacZ expression and was completely inactive at E11.5. Together, these results suggest that MEF2C acts on its own promoter to amplify and maintain its expression in differentiating myoblasts and differentiated muscle. Other members of the MEF2 family also become expressed at high levels in the somite myotome after E9.5 (Edmondson et al., 1994), which could further reinforce the expression of Mef2c.
Our results suggest that myogenic bHLH transcription factors are required for the initial activation of Mef2c expression in vivo. Although MEF2 proteins are not sufficient to activate Mef2c transcription, they cooperate with the myogenic bHLH proteins, which provide the muscle specificity necessary to direct the expression of Mef2c in cells of the myogenic lineage throughout development and into adulthood. A model of how myogenic bHLH and MEF2 proteins might cooperatively regulate the expression of Mef2c during skeletal myogenesis is shown in Fig. 9A.
|
Crossregulation of myogenic bHLH and MEF2 genes
The structure of the Mef2c skeletal muscle promoter/enhancer is remarkably similar to that of the myogenin and MRF4 promoters, both of which contain MyoD- and MEF2-binding sites (Edmondson et al., 1992; Cheng et al., 1993; Yee and Rigby, 1993; Black et al., 1995; Naidu et al., 1995). Like Mef2c, myogenin and MRF4 are upregulated during myocyte differentiation, presumably through direct transactivation by bHLH and MEF2 factors. This type of crosstalk provides a powerful mechanism for amplification of both types of regulatory genes, thereby reinforcing and stabilizing the transcriptional program for myogenesis.
In transfected cells, MyoD and MEF2 can cooperatively activate transcription through a binding site for either factor alone (Molkentin et al., 1995). By contrast, mutation of either the MEF2 or MyoD site in the Mef2c promoter severely diminished transcriptional activity in vivo. These findings suggest that the levels of expression of the endogenous factors are insufficient to activate transcription solely through protein-protein interactions and without binding sites for both factors. This further demonstrates the existent crossregulation between the myogenic bHLH transcription factors and the MEF2 proteins in skeletal muscle development. A model to account for the regulation of Mef2c transcription during myogenesis is shown in Fig. 9B.
The Drosophila Mef2 gene is also expressed at high levels in differentiated skeletal muscle fibers (Lilly et al., 1995; Bour et al., 1995). Previously, we and others showed that transcription of Mef2 is controlled by an array of independent enhancers that are activated in specific subsets of myocytes at distinct developmental stages (Cripps et al., 1998; Cripps et al., 1999; Nguyen and Xu, 1998). Recently, we identified an enhancer that directs Mef2 transcription specifically in differentiated myofibers of the Drosophila embryo (R. Cripps and E. N. O., unpublished). This enhancer contains both a high-affinity MEF2-binding site that is essential for transcriptional activity and an E-box that is necessary for full activity. Thus, the type of positive auto- and crossregulatory loops identified in the present study seems likely to reflect an evolutionarily conserved mechanism for the control of MEF2 gene expression in the skeletal muscle lineage.
Modular regulation of Mef2c transcription
A common theme that has emerged through the analysis of muscle gene transcription is the modularity of cis-regulatory elements, in which multiple independent regulatory regions are required to generate the complete spatiotemporal expression pattern of a gene throughout development (Firulli and Olson, 1997). Our results demonstrate the existence of two independent regulatory regions that direct Mef2c transcription in discrete, but overlapping, sets of embryonic skeletal muscle cells.
A distal upstream region (1058/507) activates transcription specifically in cells from the dorsomedial myotome and ventrolateral dermomyotome, which give rise to extreme epaxial, as well as hypaxial and limb muscles, respectively. To our knowledge, these two populations of muscle cells related and have not been previously recognized as being molecularly distinct from other mnyogenic populations. Thus, this Mef2c transgene has revealed unique compartments of the myogenic lineage. The specific transcription factors that activate this distal regulatory region remain to be identified.
The proximal 500bp regulatory region of Mef2c acts independently of this distal enhancer and is sufficient to direct expression of lacZ in a pattern that appears to recapitulate the expression pattern of the endogenous Mef2c gene during pre- and postnatal skeletal muscle development. Although our studies do not allow us to conclude that these two regions are solely responsible for Mef2c transcription in the skeletal muscle lineage, we have found no other skeletal muscle regulatory elements within 24 kb of genomic DNA analyzed.
In addition to its expression in the skeletal muscle lineage, Mef2c is expressed in the developing heart, in specific sets of neurons in the brain, and in the spleen (Lyons et al., 1995; Martin et al., 1993; Edmondson et al., 1994). Unlike many other muscle-specific enhancers, the Mef2c enhancer described here is absolutely specific for the skeletal muscle lineage with no expression in the heart or other organs, suggesting the presence of completely separate regulatory mechanisms for expression in tissues other than skeletal muscle. We have not yet identified the regulatory elements that control Mef2c transcription in the latter cell types. However, our studies suggest that cardiac and neural transcripts for Mef2c contain unique 5' exons that probably reflect alternate promoters in these tissues. The mechanisms that regulate MEF2 expression in these cell types and whether MEF2 positively autoregulates its expression in cardiac myocytes and neurons, as in skeletal myocytes, is currently under investigation.
![]() |
ACKNOWLEDGMENTS |
---|
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Black, B. L., Martin, J. F. and Olson, E. N. (1995). The mouse MRF4 promoter is trans-activated directly and indirectly by muscle-specific transcription factors. J. Biol. Chem. 270, 2889-2892.
Black, B. L. and Olson, E. N. (1998). Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu. Rev. Cell Dev. Biol. 14, 167-196.[Medline]
Bour, B. A., OBrien, M. A., Lockwood, W. L., Goldstein, E. S., Bodmer, R., Taghert, P. H., Abmayr, S. M. and Nguyen, H. T. (1995). Drosophila MEF2, a transcription factor that is essential for myogenesis. Genes Dev. 9, 730-741.[Abstract]
Braun, T., Buschhausen-Denker, G., Bober, E., Tannich, E. and Arnold, H. H. (1989). A novel human muscle factor related to but distinct from MyoD1 induces myogenic conversion in 10T1/2 fibroblasts. EMBO J. 8, 701-709[Abstract]
Braun, T., Rudnicki, M. A., Arnold, H. H. and Jaenisch, R. (1992). Targeted inactivation of the muscle regulatory gene Myf-5 results in abnormal rib development and perinatal death. Cell 71, 369-382.[Medline]
Breitbart, R. E., Liang, C. S., Smoot, L. B., Laheru, D. A., Mahdavi, V. and Nadal-Ginard, B. (1993). A fourth human MEF2 transcription factor, hMEF2D, is an early marker of the myogenic lineage. Development 118, 1095-1106.
Buchberger, A., Ragge, K. and Arnold, H. H. (1994). The myogenin gene is activated during myocyte differentiation by pre- existing, not newly synthesized transcription factor MEF-2. J. Biol. Chem. 269, 17289-17296.
Chakraborty, T., Brennan, T. and Olson, E. (1991). Differential trans-activation of a muscle-specific enhancer by myogenic helix-loop-helix proteins is separable from DNA binding. J. Biol. Chem. 266, 2878-2882.
Chambers, A. E., Kotecha, S., Towers, N. and Mohun, T. J. (1992). Muscle-specific expression of SRF-related genes in the early embryo of Xenopus laevis. EMBO J. 11, 4981-4991.[Abstract]
Cheng, T.-C., Hanley, T. A., Mudd, J., Merlie, J. P. and Olson, E. N. (1992). Mapping of myogenin transcription during embryogenesis using transgenes linked to the myogenin control region. J. Cell Biol. 119, 1649-1656.[Abstract]
Cheng, T.-C., Wallace, M. C., Merlie, J. P. and Olson, E. N. (1993). Separable regulatory elements governing myogenin transcription in mouse embryogenesis. Science 261, 215-218.[Medline]
Christ, B., Jacob, H. B. and Jacob, M. (1978). On the formation of the myotomes in avian embryos. An experimental and scanning electron microscopic study. Experentia 34, 514-516.
Cripps, R. M., Black, B. L., Zhao, B., Lien, C. L., Schulz, R. A. and Olson, E. N. (1998). The myogenic regulatory gene Mef2 is a direct target for transcriptional activation by Twist during Drosophila myogenesis. Genes Dev. 12, 422-434.
Cripps, R. M., Zhao, B. and Olson, E. N. (1999). Transcription of the myogenic regulatory gene Mef2 in cardiac, somatic, and visceral muscle cell lineages is regulated by a Tinman-dependent core enhancer. Dev. Biol. 215, 420-430.[Medline]
Cserjesi, P. and Olson, E. N. (1991). Myogenin induces the myocyte-specific enhancer binding factor MEF-2 independently of other muscle-specific gene products. Mol. Cell Biol. 11, 4854-4862.[Medline]
Cserjesi, P., Lilly, B., Hinkley, C., Perry, M. and Olson, E. N. (1994). Homeodomain protein MHox and MADS protein myocyte enhancer-binding factor-2 converge on a common element in the muscle creatine kinase enhancer. J. Biol. Chem. 269, 16740-16745.
Davis, R. L., Weintraub, H. and Lassar, A. B. (1987). Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51, 987-1000.[Medline]
Denetclaw, W. F., Jr, Christ, B. and Ordahl, C. P. (1997). Location and growth of epaxial myotome precursor cells. Development 124, 1601-1610.
Edmondson, D. G. and Olson, E. N. (1989). A gene with homology to the myc similarity region of MyoD1 is expressed during myogenesis and is sufficient to activate the muscle differentiation program. Genes Dev. 3, 628-640.[Abstract]
Edmondson, D. G., Cheng, T. C., Cserjesi, P., Chakraborty, T. and Olson, E. N. (1992). Analysis of the myogenin promoter reveals an indirect pathway for positive autoregulation mediated by the muscle-specific enhancer factor MEF-2. Mol. Cell. Biol. 12, 3665-3677.[Abstract]
Edmondson, D. G., Lyons, G. E., Martin, J. F. and Olson, E. N. (1994). Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis. Development 120, 1251-1263.
Firulli, A. B. and Olson, E. N. (1997). Modular regulation of muscle gene transcription: a mechanism for muscle cell diversity. Trends Genet. 13, 364-369.[Medline]
Gossett, L. A., Kelvin, D. J., Sternberg, E. A. and Olson, E. N. (1989). A new myocyte-specific enhancer-binding factor that recognizes a conserved element associated with multiple muscle-specific genes. Mol. Cell Biol. 9, 5022-5033.[Medline]
Harland, R. and Weintraub, H. (1985). Translation of mRNA injected into Xenopus oocytes is specifically inhibited by antisense RNA. J. Cell Biol. 101, 1094-1099.[Abstract]
Hasty, P., Bradley, A., Morris, J. H., Edmondson, D. G., Venuti, J. M., Olson, E. N. and Klein, W. H. (1993). Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene. Nature 364, 501-506.[Medline]
Hauschka, S. D. (1994). Muscles, anatomy and histology. In Myology: Basic and Clinical (ed. A. Engel and C. Franzini-Armstrong), pp. 3-73. New York: McGraw-Hill.
Hinterberger, T. J., Sassoon, D. A., Rhodes, S. J. and Konieczny, S. F. (1991). Expression of the muscle regulatory factor MRF4 during somite and skeletal myofiber development. Dev. Biol. 147, 144-156.[Medline]
Horton, R. A. and Pease, L. R. (1991). Recombination and mutagenesis of DNA sequences using PCR. In Directed Mutagenesis: A Practical Approach. New York, Oxford: IRL Press.
Kaehn, K., Jacob, H. J., Christ, B., Hinrichsen, K. and Poelmann, R. E. (1988). The onset of myotome formation in the chick. Anat. Embryol. 177, 191-201.[Medline]
Kothary, R., Clapoff, S., Darling, S., Perry, M. D., Moran, L. A. and Rossant, J. (1989). Inducible expression of an hsp68-lacZ hybrid gene in transgenic mice. Development 105, 707-714.[Abstract]
Lassar, A. B., Davis, R. L., Wright, W. E., Kadesch, T., Murre, C., Voronova, A., Baltimore, D. and Weintraub, H. (1991). Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell 66, 305-315.[Medline]
Leifer, D., Krainc, D., Yu, Y. T., McDermott, J., Breitbart, R. E., Heng, J., Neve, R. L., Kosofsky, B., Nadal-Ginard, B. and Lipton, S. A. (1993). MEF2C, a MADS/MEF2-family transcription factor expressed in a laminar distribution in cerebral cortex. Proc. Natl. Acad. Sci. USA 90, 1546-1550.[Abstract]
Lien, C-L., Wu, C., Mercer, B., Webb, R., Richardson, J. A. and Olson, E. N. (1999). Control of early cardiac-specific transcription of Nkx2-5 by a GATA-dependent enhancer. Development 126, 75-84.
Lilly, B., Zhao, B., Ranganayakulu, G., Paterson, B. M., Schulz, R. A. and Olson, E. N. (1995). Requirement of MADS domain transcription factor D-MEF2 for muscle formation in Drosophila. Science 267, 688-693.[Medline]
Lin, Q., Schwarz, J., Bucana, C. and Olson, E. N. (1997). Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 276, 1404-1407.
Lin, Q., Lu, J., Yanagisawa, H., Webb, R., Lyons, G. E., Richardson, J. A. and Olson, E. N. (1998). Requirement of the MADS-box transcription factor MEF2C for vascular development. Development 125, 4565-4574.
Lyons, G. E., Micales, B. K., Schwarz, J., Martin, J. F. and Olson, E. N. (1995). Expression of mef2 genes in the mouse central nervous system suggests a role in neuronal maturation. J. Neurosci. 15, 5727-5738.[Abstract]
Martin, J. F., Schwarz, J. J. and Olson, E. N. (1993). Myocyte enhancer factor (MEF) 2C: a tissue-restricted member of the MEF- 2 family of transcription factors. Proc. Natl. Acad. Sci. USA 90, 5282-5286.[Abstract]
Martin, J. F., Miano, J. M., Hustad, C. M., Copeland, N. G., Jenkins, N. A. and Olson, E. N. (1994). A Mef2 gene that generates a muscle-specific isoform via alternative mRNA splicing. Mol. Cell. Biol. 14, 1647-1656.[Abstract]
McDermott, J. C., Cardoso, M. C., Yu, Y. T., Andres, V., Leifer, D., Krainc, D., Lipton, S. A. and Nadal-Ginard, B. (1993). hMEF2C gene encodes skeletal muscle- and brain-specific transcription factors. Mol. Cell. Biol. 13, 2564-2577.[Abstract]
McFadden, D. G., Charite, J., Richardson, J. A., Srivastava, D., Firulli, A. B. and Olson, E. N. (2000). A GATA-dependent right ventricular enhancer controls dHAND transcription in the developing heart. Development 127, 5331-5341.
McKinsey, T. A., Zhang, C. L., Lu, J. and Olson, E. N. (2000a). Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 408, 106-111.[Medline]
McKinsey, T. A., Zhang, C. L. and Olson, E. N. (2000b). Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc. Natl. Acad. Sci. USA 97, 14400-14405.
Molkentin, J. D. and Olson, E. N. (1996). Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors. Proc. Natl. Acad. Sci. USA 93, 9366-9373.
Molkentin, J. D., Black, B. L., Martin, J. F. and Olson, E. N. (1995). Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins. Cell 83, 1125-1136.[Medline]
Nabeshima, Y., Hanaoka, K., Hayasaka, M., Esumi, E., Li, S. and Nonaka, I. (1993). Myogenin gene disruption results in perinatal lethality because of severe muscle defect. Nature 364, 532-535.[Medline]
Naidu, P. S., Ludolph, D. C., To, R. Q., Hinterberger, T. J. and Konieczny, S. F. (1995). Myogenin and MEF2 function synergistically to activate the MRF4 promoter during myogenesis. Mol. Cell. Biol. 15, 2707-2718.[Abstract]
Nguyen, H. T. and Xu, X. (1998). Drosophila mef2 expression during mesoderm development is controlled by a complex array of cis-acting regulatory modules. Dev. Biol. 204, 550-566.[Medline]
Olson, E. N. and Klein, W. H. (1994). bHLH factors in muscle development: dead lines and commitments, what to leave in and what to leave out. Genes Dev. 8, 1-8.[Medline]
Ordahl, C. P., Berdougo, E., Venters, S. J. and Denetclaw, W. F. (2001). The dermomyotome dorsomedial lip drives growth and morphogenesis of both the primary myotome and dermomyotome epithelium. Development 128, 1731-1744.
Ott, M. O., Bober, E., Lyons, G., Arnold, H. and Buckingham, M. (1991). Early expression of the myogenic regulatory gene, myf-5, in precursor cells of skeletal muscle in the mouse embryo. Development 111, 1097-1107.[Abstract]
Pollock, R. and Treisman, R. (1991). Human SRF-related proteins: DNA-binding properties and potential regulatory targets. Genes Dev. 5, 2327-2341.[Abstract]
Ranganayakulu, G., Zhao, B., Dokidis, A., Molkentin, J. D., Olson, E. N. and Schulz, R. A. (1995). A series of mutations in the D-MEF2 transcription factor reveal multiple functions in larval and adult myogenesis in Drosophila. Dev. Biol. 171, 169-181.[Medline]
Rawls, A., Valdez, M. R., Zhang, W., Richardson, J., Klein, W. H. and Olson, E. N. (1998). Overlapping functions of the myogenic bHLH genes MRF4 and MyoD revealed in double mutant mice. Development 125, 2349-2358.
Rhodes, S. J. and Konieczny, S. F. (1989). Identification of MRF4: a new member of the muscle regulatory factor gene family. Genes Dev. 3, 2050-2061.[Abstract]
Rudnicki, M. A., Braun, T., Hinuma, S. and Jaenisch, R. (1992). Inactivation of MyoD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently normal muscle development. Cell 71, 383-390.[Medline]
Rudnicki, M. A., Schnegelsberg, P. N., Stead, R. H., Braun, T., Arnold, H. H. and Jaenisch, R. (1993). MyoD or Myf-5 is required for the formation of skeletal muscle. Cell 75, 1351-1359.[Medline]
Sassoon, D., Lyons, G., Wright, W. E., Lin, V., Lassar, A., Weintraub, H. and Buckingham, M. (1989). Expression of two myogenic regulatory factors myogenin and MyoD1 during mouse embryogenesis. Nature 341, 303-307.[Medline]
Smith, T. H., Kachinsky, A. M. and Miller, J. B. (1994). Somite subdomains, muscle cell origins, and the four muscle regulatory factor proteins. J. Cell Biol. 127, 95-105.[Abstract]
Ticho, B. S., Stainier, D. Y., Fishman, M. C. and Breitbart, R. E. (1996). Three zebrafish MEF2 genes delineate somitic and cardiac muscle development in wild-type and mutant embryos. Mech. Dev. 59, 205-218.[Medline]
Wang, D. Z., Reiter, R. S., Lin, J. L., Wang, Q., Williams, H. S., Krob, S. L., Schultheiss, T. M., Evans, S. and Lin, J. J. (1999). Requirement of a novel gene, Xin, in cardiac morphogenesis. Development 126, 1281-1294.
Yee, S. P. and Rigby, P. W. (1993). The regulation of myogenin gene expression during the embryonic development of the mouse. Genes Dev. 7, 1277-1289.[Abstract]
Yu, Y. T., Breitbart, R. E., Smoot, L. B., Lee, Y., Mahdavi, V. and Nadal-Ginard, B. (1992). Human myocyte-specific enhancer factor 2 comprises a group of tissue- restricted MADS box transcription factors. Genes Dev. 6, 1783-1798.[Abstract]